1. NK Cell Degranulation Triggered by Rituximab Identifies Potential Markers of Subpopulations with Enhanced Cytotoxicity toward Malignant B Cells.
- Author
-
Wlodarczyk M, Torun A, Zerrouqi A, and Pyrzynska B
- Subjects
- Humans, OX40 Ligand metabolism, OX40 Ligand genetics, Antibody-Dependent Cell Cytotoxicity drug effects, Cell Line, Tumor, Lysosomal-Associated Membrane Protein 1 metabolism, B-Lymphocytes immunology, B-Lymphocytes drug effects, B-Lymphocytes metabolism, Antineoplastic Agents, Immunological pharmacology, Rituximab pharmacology, Killer Cells, Natural immunology, Killer Cells, Natural drug effects, Killer Cells, Natural metabolism, Cell Degranulation drug effects
- Abstract
A promising strategy in cancer immunotherapy is to restore or enhance the cytotoxicity of NK cells, among others, by activating the mechanism of antibody-dependent cellular cytotoxicity (ADCC). Monoclonal antibodies targeting tumor antigens, such as rituximab (targeting CD20), induce NK cell-mediated ADCC and have been used to treat B cell malignancies, such as non-Hodgkin lymphoma, but not always successfully. The aim of this study was to analyze the gene expression profile of the NK cells involved in the cytolytic response stimulated by rituximab. NK cells were co-cultured with rituximab-opsonized Raji cells. Sorting into responder and non-responder groups was based on the presence of CD107a, which is a degranulation marker. RNA-seq results showed that the KIT and TNFSF4 genes were strongly down-regulated in the degranulating population of NK cells (responders); this was further confirmed by qRT-PCR. Both genes encode surface proteins with cellular signaling abilities, namely c-KIT and the OX40 ligand. Consistent with our findings, c-KIT was previously reported to correlate inversely with cytokine production by activated NK cells. The significance of these findings for cancer immunotherapy seems essential, as the pharmacological inhibition of c-KIT and OX40L, or gene ablation, could be further tested for the enhancement of the anti-tumor activity of NK cells in response to rituximab.
- Published
- 2024
- Full Text
- View/download PDF